Bicalutamide-Associated Acute Liver Injury and Migratory Arthralgia: A Rare but Clinically Important Adverse Effect

  title={Bicalutamide-Associated Acute Liver Injury and Migratory Arthralgia: A Rare but Clinically Important Adverse Effect},
  author={Helga M. Gretarsdottir and Elin Bjornsdottir and E. Bjornsson},
  journal={Case Reports in Gastroenterology},
  pages={266 - 270}
We describe a case of acute liver injury and migratory arthralgia in a patient receiving bicalutamide treatment for prostate cancer. A 67-year-old male with metastatic prostate cancer presented with a 6-day history of migratory arthralgia. He had been undergoing treatment with bicalutamide for 4 months; 3 weeks prior to symptom appearance the bicalutamide dose had been increased. He had no other symptoms. Liver tests and inflammatory markers were markedly elevated. Serology for hepatitis… Expand


Bicalutamide-induced hepatotoxicity: A rare adverse effect
An 81-year-old African American male with metastatic prostate neoplasm presented with nonspecific symptoms along with jaundice of 1-day duration and bicalutamide was discontinued and he showed improvement of clinical and laboratory abnormalities within days. Expand
Bicalutamide‐Associated Fulminant Hepatotoxicity
A 59‐year‐old man with metastatic prostate carcinoma treated with bicalutamide as part of androgen deprivation therapy before starting chemotherapy died 8 days after bicalUTamide therapy was begun secondary to multiorgan failure, most likely as a result of fulminant hepatotoxicity. Expand
Atypical onset of bicalutamide-induced liver injury.
A case of hepatotoxicity secondary to bicalutamide use is reported, in this case, hepatic injury occurred 5 mo after treatment initiation, based on this rare case of delayed liver injury. Expand
Clopidogrel-Induced Recurrent Polyarthritis
The case of a 64-year-old man who reported symptoms of fever and joint pains following initiation of therapy with clopidogrel and who reported experiencing a similar arthritis after he received a loading dose of clopIDogrel prior to a diagnostic coronary angiography in the past is described. Expand
Migratory Polyarthritis as a Paraneoplastic Syndrome
A patient who initially presented with asymmetric inflammatory polyarthritis who was later diagnosed with bronchogenic carcinoma is presented and a brief discussion of the pathophysiology and management of CP is presented. Expand
Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.
Mortality from DILI is significantly higher in individuals with pre-existing liver disease or concomitant severe skin reactions compared with patients without, and additional studies are needed to confirm the association between azithromycin and increased DILi in patients with chronic liver disease. Expand
Propylthiouracil hypersensitivity: report of two patients with vasculitis and review of the literature.
Two patients with a hypersensitivity vasculitis in association with propylthiouracil (PTU) administration are described. Although both patients presented with a cutaneous eruption, our first patientExpand
Bicalutamide: clinical pharmacokinetics and metabolism.
  • I. Cockshott
  • Chemistry, Medicine
  • Clinical pharmacokinetics
  • 2004
Bicalutamide is a nonsteroidal pure antiandrogen given at a dosage of 150 mg once daily as monotherapy for the treatment of early (localised or locally advanced) nonmetastatic prostate cancer and has the potential to inhibit CYP3A4 and, to a lesser extent, CYP2C9, 2C19 and 2D6. Expand
Drug-related hepatotoxicity and hepatic failure following combined androgen blockade
The case of a patient with acute hepatic failure associated with the use of bicalutamide is reported, which is an adverse reaction more frequently noticed during androgen deprivation therapy with antiandrogen. Expand
Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events
An important relationship between a compound's metabolism profile and reports of hepatic adverse events is found and compounds with both significant hepatic metabolism and daily dose were significantly more hepatotoxic than compounds belonging to other groups. Expand